The pandemic caused by severe acute respiratory syndrome coronavirus 2 is sweeping the world, threatening millions of lives and drastically altering our ways of living. According to current studies, failure to either activate or eliminate inflammatory responses timely and properly at certain stages could result in the progression of the disease. In other words, robust immune responses to coronavirus disease 2019 (COVID-19) are critical. However, they do not theoretically present in some special groups of people, including the young, the aged, patients with autoimmunity or cancer. Differences also do occur between men and women. Our immune system evolves to ensure delicate coordination at different stages of life. The innate immune cells mainly consisted of myeloid lineage cells, including neutrophils, basophils, eosinophils, dendritic cells and mast cells; they possess phagocytic capacity to different degrees at different stages of life. They are firstly recruited upon infection and may activate the adaptive immunity when needed. The adaptive immune cells, on the other way, are comprised mainly of lymphoid lineages. As one grows up, the adaptive immunity matures and expands its memory repertoire, accompanied by an adjustment in quantity and quality. In this review, we would summarise and analyse the immunological characteristics of these groups from the perspective of the immune system 'evolution' as well as 'revolution' that has been studied and speculated so far, which would aid the comprehensive understanding of COVID-19 and personalised-treatment strategy.
基金:
Hubei Provincial Natural Science Foundation of China [2019CFA062]; Beijing Kanghua Foundation for the Development of Traditional Chinese and Western Medicine [KH-2021-LLZX-074]; Strategic Collaborative Research Program of the Ferring Institute of Reproductive Medicine Ferring Pharmaceuticals; Chinese Academy of Sciences [FIRMSCOV05]; National Natural Science Foundation of China [81672085, 81873843]; Chinese Medical Association of Clinical Medicine special funds for scientific research projects [17020400709]; National Clinical Research Center for Obstetrics and Gynecology [2015BAI13B05]; National Science and Technology Pillar program of China [2014BAI05B05]; Fundamental Research Funds for the Central Universities [2017KFYXJJ102, 2019KFYXKJC053]
语种:
外文
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2021]版:
大类|3 区医学
小类|3 区生化与分子生物学3 区医学:研究与实验
最新[2025]版:
大类|3 区医学
小类|3 区生化与分子生物学3 区医学:研究与实验
JCR分区:
出版当年[2020]版:
Q1BIOCHEMISTRY & MOLECULAR BIOLOGYQ2MEDICINE, RESEARCH & EXPERIMENTAL
最新[2023]版:
Q1BIOCHEMISTRY & MOLECULAR BIOLOGYQ2MEDICINE, RESEARCH & EXPERIMENTAL
第一作者单位:[1]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Obstet & Gynecol, Wuhan 430030, Hubei, Peoples R China
通讯作者:
推荐引用方式(GB/T 7714):
Lv Dan,Hu Bai,Lin Xingguang,et al.Immunopathogenesis of patients with COVID-19: from the perspective of immune system 'evolution' and 'revolution'[J].EXPERT REVIEWS IN MOLECULAR MEDICINE.2022,24:doi:10.1017/erm.2022.12.
APA:
Lv, Dan,Hu, Bai,Lin, Xingguang,Wang, Renjie,Wu, Di...&Deng, Dongrui.(2022).Immunopathogenesis of patients with COVID-19: from the perspective of immune system 'evolution' and 'revolution'.EXPERT REVIEWS IN MOLECULAR MEDICINE,24,
MLA:
Lv, Dan,et al."Immunopathogenesis of patients with COVID-19: from the perspective of immune system 'evolution' and 'revolution'".EXPERT REVIEWS IN MOLECULAR MEDICINE 24.(2022)